Overview
- The efficacy of many drugs meant for the brain tends to be undermined as 98% of them cannot disrupt the blood-brain barrier (BBB).
- The team has thus developed an ultrasound driving system for transcranial brain drug delivery that can be used for localized and temporal BBB disruption, thereby promoting drug efficacy.
- Easy to perform during outpatient visits, this noninvasive approach allows for repeated administration in low dosage and causes no harm to local tissue.
Development Process
Over the course of this project under the Applied Research Incubation Program, the team completed clinicalization strategy analysis, market analysis, international regulatory analysis, business model feasibility analysis, technical operability analysis, critical technology R&D roadmap, preclinical trials planning, and establishment of a technological development model for the future. After NaviFUS Corp. was established on March 12, 2015, the team continued to offer assistance in product commercialization.